Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
354 Leser
Artikel bewerten:
(2)

Sophie's Bionutrients: Food Pioneers Sophie's Bionutrients And NewFish Join Forces To Develop Dairy Alternatives From Microalgae

Finanznachrichten News

AMSTERDAM and AUCKLAND, New Zealand, Sept. 15, 2022 /PRNewswire/ -- Sophie's Bionutrients and NewFish, two pioneers in the field of microalgae protein fermentation, with the support of New Zealand-based marine research powerhouse, Cawthron Institute, and Netherlands-based leading food university, Wageningen University & Research, have decided to collaborate internationally to unlock microalgae's future in food nutrition.

Sophie's Bionutrients Microalgae Milk alternative

Global food challenges require alternative solutions.

Fueling the growing world population requires ensuring the supply of climate-friendly and ethically-produced proteins, new protein sources, and novel food production technologies. While many are starting to enter the plant-based food category globally, few companies are driving R&D efforts to offer GMO-free dairy alternatives and specialized ingredients.

Since 2022, a new wave of modern food companies are joining forces to accelerate innovation in microalgae and share upstream and downstream resources. Collectively, they have a shared global mission to develop microalgae as the base for sustainable nutrition and novel food products that eliminate animal suffering and promise an ecological footprint far superior to that of intensive industrial farming.

One leading company is Sophie's Bionutrients, a B2B food technology company on a mission to create plant-based, protein-rich alternatives to meat and seafood using microalgae. The Temasek Foundation-backed startup, operating between Singapore and the Netherlands, in 2021 announced to be the world's first foodtech company to use microalgae to develop 100% plant-based and sustainable alternative proteins for use in dairy and other novel foods.

Another high growth startup, NewFish, is a leading New Zealand biotech and novel ingredients company specializing in fermentation, production, R&D, commercialisation and manufacturing of novel seafoods and proteins derived from microalgae. The company is headquartered in Auckland and works closely with the Cawthron Institute, a leading world-leading marine science park headquartered in Nelson, New Zealand along with other New Zealand institutes and engineering partners.

Microalgae derived NewFish Bytes were launched at New Zealand's leading food festival 'Wellington on a Plate' this August

Both companies are at the forefront of advancing microalgae protein research and product development in their respective regions. Their collaboration spans their global value chains, including shared research and development, co-development of microalgae strains, ingredients supply for manufacturing, and commercializing new food and alternative dairy solutions.

The starting point for deeper collaboration

"We are pleased to form this strategic partnership with Sophie's Bionutrients, already an industry leader in microalgae fermentation and proteins. NewFish, Cawthron Institute, and New Zealand have a complementary focus regarding novel ingredients, whereas we also have our endemic microalgae strains and species. This partnership will serve as a starting point for deeper global collaboration between the parties and will accelerate the microalgae foods and nutrition industry. We are solving a global issue, which requires a collective solution," said Hamish Howard, General Manager of NewFish.

"Together with NewFish and Cawthron Institute, we are working to overcome the challenges of obtaining sufficient microalgae strains, scaling production capacity, and bringing online sufficient global supply to make available affordable, taste and consistent foods made from microalgae. We are delighted about this Singapore-New Zealand-Netherlands-Taiwan partnership in which we are working together on the future of food," emphasized Kirin Tsuei, co-founder and CCO of Sophie's Bionutrients.

Sophie's Bionutrients Logo

About Sophie's Bionutrients

Sophie's Bionutrients, a B2B food technology company operating between Singapore and the Netherlands, is on a mission to unleash the limitless possibilities of nature, restore our planet and eliminate food allergies. It aims to achieve this by creating plant-based, protein-rich alternatives to meat and seafood using microalgae.

About NewFish

NewFish is a fast-growing New Zealand biotech and commercialization venture fermenting New Zealand microalgae and underutilized seafood to re-imagine new sustainable foods and ingredients to help feed our world.

Photo - https://mma.prnewswire.com/media/1899535/Sophie_s_Bionutrients_Microalgae_Milk_alternative.jpg
Photo - https://mma.prnewswire.com/media/1899536/Microalgae_derived_NewFish__Bytes_launched_New_Zealand_s_leading_food_festival.jpg
Logo - https://mma.prnewswire.com/media/1672795/SophiesBioNutrients_Logo.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.